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Diabetes is a major risk factor for atherosclerosis.
Although atherosclerosis is initiated by deposition
of cholesterol-rich lipoproteins in the artery wall,
the entry of inflammatory leukocytes into lesions
fuels disease progression and impairs resolution.
We show that diabetic mice have increased numbers
of circulating neutrophils and Ly6-Chi monocytes,
reflecting hyperglycemia-induced proliferation and
expansion of bone marrow myeloid progenitors and
release of monocytes into the circulation. Increased
neutrophil production of S100A8/S100A9, and its
subsequent interaction with the receptor for
advanced glycation end products on common
myeloid progenitor cells, leads to enhanced myelo-
poiesis. Treatment of hyperglycemia reduces mono-
cytosis, entry of monocytes into atherosclerotic
lesions, and promotes regression. In patients with
type 1 diabetes, plasma S100A8/S100A9 levels
correlate with leukocyte counts and coronary artery
disease. Thus, hyperglycemia drives myelopoiesis
and promotes atherogenesis in diabetes.
INTRODUCTION
Type 1 (T1DM) and type 2 diabetes mellitus (T2DM) are associ-
ated with an increased risk of coronary artery disease (CAD).
Elevated white blood cell (WBC) counts are also an independent
risk factor for CAD (Coller, 2005; Danesh et al., 1998). Increased
leukocyte levels are seen in diabetics (Ford, 2002; Persson et al.,
1998; Schmidt et al., 1999; Vuckovic et al., 2007; Woo et al.,
2011) and are associated with a higher prevalence of CAD
(Orchard et al., 2003). Moreover, there is evidence that increased
levels of circulating monocytes, especially inflammatory Ly6C+
CCR2+ monocytes (Swirski et al., 2007; Tacke et al., 2007),
and neutrophils (Drechsler et al., 2010) leads to increased entry
into plaques and drives lesion progression. Diabetes leads to aCvariety of metabolic changes including altered insulin signaling,
greater adipose lipolysis, hyperlipidemia, and hyperglycemia.
However, which of these mechanisms might be responsible for
leukocytosis in diabetes is unknown.
Because of the recent introduction of potent cholesterol-
reduction therapies, it is now clear that markedly reducing
plasma low-density lipoprotein (LDL) cholesterol levels can pro-
mote atherosclerotic lesion regression in humans (Nicholls et al.,
2011). However, diabetics with CAD appear to have impaired
regression of atherosclerosis when their plasma lipid levels are
controlled (Duff and Payne, 1950; Hiro et al., 2010; Parathath
et al., 2011). We have recently used mouse models in which
plasma levels of atherogenic lipoproteins were acutely lowered
to carry out mechanistic studies of atherosclerosis regression
(Feig et al., 2010; Parathath et al., 2011; Trogan et al., 2006). In
this model, diabetic mice show markedly impaired regression
compared to controls, despite similar plasma lipid lowering
(Parathath et al., 2011); however, the underlying mechanisms
were not defined.
The goals of this study were 3-fold: (1) to determine the
mechanisms responsible for monocytosis and neutrophilia in
diabetes; (2) to assess the relevance of hyperglycemia to athero-
sclerosis and, specifically, its potential role in the impaired
regression of atherosclerosis in diabetes; and (3) to determine
if similar mechanisms might be at work in a human population
with type 1 diabetes.RESULTS
Leukocytosis Is Hyperglycemia Dependent
To investigate if hyperglycemia promotesmonocytosis, we stud-
ied twomousemodels of insulin-deficient diabetes on chow diet:
chemical (streptozotocin, STZ) and genetic (C57BL/6-Ins2Akita)
islet cell destruction. In both diabetic models, we observed a
significant increase in the number of circulating monocytes (pre-
dominantly the Ly6-Chi proinflammatory subset) and neutrophils
(Figures 1A–1D) but not lymphocytes (Figures S1A and S1B). To
determine if these changes were induced by hyperglycemia,
plasma glucose levels were reduced using a sodium glucose
cotransporter 2 inhibitor (SGLT2i); insulin and cholesterol levelsell Metabolism 17, 695–708, May 7, 2013 ª2013 Elsevier Inc. 695
Figure 1. Leukocytosis Develops in Response to Hyperglycemia via Expansion and Proliferation of BM Progenitor Cells
(A andB) Chow-fed, nondiabeticWT (C57BL/6), STZ-diabetic, and Akita diabeticmicewere treatedwith SGLT2i (5mg/kg; ISIS Pharmaceuticals) in drinkingwater
for 4 weeks. Representative flow cytometry plots of blood leukocyte subsets from STZ-diabetic (A) and Akita diabetic (B) mice.
(C and D) Quantification of monocyte subsets and neutrophils in STZ-diabetic (C) and Akita diabetic (D) mice.
(E–H) HSPC, CMP, and GMP analysis in the BM. The percentage of the respective populations in STZ-diabetic (E) and Akita diabetic (F) mice, and cell-cycle
(G2/M phase) analysis in STZ-diabetic (G) and Akita diabetic (H) mice was performed by flow cytometry. For all experiments, n = 10–12/group. *p < 0.05 versus all
groups, and ^p < 0.05 versus WT + STZ or Akita. All values are means ± SEM.
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reduced the levels of monocytes and neutrophils, suggesting
a direct role for hyperglycemia in promoting leukocytosis.
Leukocytosis was not due to decreased leukocyte apoptosis
(Figure S1K). Moreover, an EdU (5-ethynyl-20-deoxyuridine)
pulse-chase experiment revealed an increase in newly formed
(EdU+) blood monocytes in diabetic mice (Figure S1L), sug-
gesting an underlying proliferative defect.
Leukocytosis Is Due to Enhanced Myelopoiesis
Leukocytosis was associated with enhancedmyelopoiesis in the
bone marrow (BM) (Figures 1E–1H) but not in the spleen (Fig-
ure S2A). The number and proliferation of granulocyte macro-
phage progenitors (GMPs) and common myeloid progenitors
(CMPs) (Figures 1E–1H) increased with diabetes, and BM cells
had a higher potential to form CFU-GM (colony-forming unit-
granulocyte-macrophage) (Figures S2B and S2C). Expansion
of myeloid progenitor cells was not due to decreased apoptosis
(Figure S2D). Surprisingly, there was no change in the number or
proliferation of hematopoietic stem and multipotent progenitor
cells (HSPCs) (Figures 1E–1H). Normoglycemia attenuated the
expansion and proliferation of CMP and GMPs in both STZ-
and Akita diabetic mice, an effect that was reproduced with a
different SGLT2i, dapagliflozin (Meng et al., 2008) (Figure S3).
Myelopoiesis Is Driven by S100A8/S100A9
Initially, we examined plasma levels of classical hemato-
poietic cytokines such as macrophage colony-stimulating factor
(M-CSF), granulocyte-macrophage (GM)-CSF, granulocyte
(G)-CSF, and interleukin (IL)-1b as potential mediators of myelo-
poiesis. We found only plasma G-CSF levels to be increased in
diabetes and reversed by lowering blood glucose (wild-type
[WT], 77 ± 7; STZ, 121 ± 7; STZ + SGLT2i, 98 ± 5 pg/ml). The
changes in G-CSF levels may explain neutrophilia and could
also contribute in part to monocytosis (Christopher et al., 2011;
Lieschke et al., 1994; Roberts, 2005; Semerad et al., 1999).
However, some studies suggest impaired effects of G-CSF in
diabetes (Ferraro et al., 2011). We therefore assessed addi-
tional potential mechanisms. Transcriptional (messenger RNA
[mRNA]) profiling analysis of circulating and BM myeloid cells
from diabetic mice (Figures S4A–S4C) revealed increased
expression of certain damage-associated molecular patterns
(DAMPs), notably S100a8, S100a9, and Hmgb1 (high-mobility
group box 1), that have been previously linked to sterile in-
flammatory responses. Plasma S100A8/S100A9 levels were
increased in both STZ- (Figure 2A) and Akita diabetic mice
(Figure S3D) and decreased by lowering blood glucose. Neu-
trophils were the predominant source of S100a8, S100a9, and
Hmgb1 (Figures S4A–S4C). Expression of S100a8 and S100a9,
but not Hmgb1, was decreased when glucose levels were
lowered (Figure 2B). We observed an increase in reactive oxygen
species (ROS) and the expression levels of the transcription
factors Klf-5 and C/ebp-a in neutrophils from STZ mice (Figures
S4D and S4E), both of which promote S100a8/S100a9 expres-
sion (Fujiu et al., 2011; Yao and Brownlee, 2010). Lowering
glucose levels corrected the increases in ROS and expression
of Klf-5 and C/ebp-a.
Next, we tested if S100A8/S100A9 (the biologically active
heterodimer) (Leukert et al., 2006) could induce proliferation ofCBM progenitor cells. Stimulation of BM cells cultured in high
glucose (HG; 25 mM) with S100A8/S100A9 induced GMP pro-
liferation (Figure 2C). Similarly, myelopoiesis was induced
by administration of S100A8/S100A9 to mice (Figure 2D).
HMGB1, which is proposed to share receptors with S100A8/
S100A9, did not promote myelopoiesis in vitro or in vivo (Fig-
ures S4F–S4I), ruling out its role in hyperglycemia-induced
myelopoiesis.
Since neutrophils are the predominant source of S100A8/
S100A9, we transplanted BM from WT and S100a9/ mice
(that also lack S100A8 protein) into WT recipients and examined
myelopoiesis in response to diabetes (Figure 2F). Mice that
received WT BM displayed enhanced myelopoiesis when
rendered diabetic, whereas diabetes failed to produce this
myeloproliferative phenotype in S100a9/-transplanted mice
(Figures 2G–I). These findings confirm a central role for
S100A8/S100A9 in diabetes-driven myelopoiesis.
S100A8/S100A9-Induced Myelopoiesis Is RAGE
Dependent
S100A8/S100A9 can signal through multiple pattern recognition
receptors, including the receptor for advanced glycation end-
products (RAGE) and TLR2/TLR4 (Hofmann et al., 1999; Vogl
et al., 2007). To identify the specific receptor(s) involved, we
cultured BM progenitor cells isolated from WT, Rage/, and
Myd88/ mice in HG-containing medium and examined the
proliferative responses to S100A8/S100A9. WT and Myd88/
BM cells showed increased proliferation in response to
S100A8/S100A9, whereas Rage/ cells did not. Thus, the
myeloproliferative effects of S100A8/S100A9 are mediated by
RAGE (Figure 3A). The importance of RAGE in diabetic myelo-
poiesis was confirmed by showing that Rage/ mice failed to
develop leukocytosis in response to diabetes (Figure 3B). Since
Rage/ BM progenitor cells did not respond to S100A8/
S100A9, we reasoned that the interaction of S100A8/S100A9
with RAGE on BM progenitor cells was important for their prolif-
eration. Although hematopoietic progenitor cells from WT mice
had a low level of cell surface expression of RAGE, elevated
levels of RAGE were found on CMPs from diabetic mice and
were reduced by glucose lowering (Figures 3C and S3E).
To further assess the role of hematopoietic-expressed RAGE,
we performed a BM transplant (BMT) study using WT mice
transplanted with WT, Myd88/, and Rage/ BM. Only mice
receiving Rage/ BM failed to show enhanced myelopoiesis
when made diabetic with STZ (Figures 3D–3G and S5A–S5C).
Further, quenching RAGE ligands in diabetic mice with soluble
RAGE attenuated hyperglycemia-induced leukocytosis and
reduced the proliferative capacity of diabetic serum (Figures
S5D–S5G). These data confirm that the interaction of S100A8/
S100A9 with RAGE on myeloid cells drives myelopoiesis in
diabetes.
RAGE-Dependent Myelopoiesis Is Not Cell Autonomous
Binding of S100A8/S100A9 to RAGE could directly stimulate
proliferation of CMPs in a cell-autonomous fashion, or alterna-
tively induce a signaling cascade leading to the production of
proliferative cytokines that act on other myeloid progenitor cells
(e.g., GMPs) in a non-cell-autonomous fashion. To distinguish
between these two possibilities, we performed a competitiveell Metabolism 17, 695–708, May 7, 2013 ª2013 Elsevier Inc. 697
Figure 2. Neutrophil-Derived S100A8/S100A9 Promotes Leukocytosis via Increased Proliferation of BM Progenitor Cells
(A) Plasma levels of S100A8/S100A9 in STZ-diabetic mice treated with SGLT2i. n = 6.
(B) mRNA expression of S100a8, S100a9, and Hmgb1 in FACS-isolated neutrophils. n = 6; *p < 0.05 versus WT, ^p < 0.05 versus WT + STZ group.
(C) Total BM cells were isolated fromWTmice and cultured in HG (25 mM, 16 hr) and stimulated with S100A8/S100A9 complex. GMP proliferation was assessed
by measuring EdU incorporation via flow cytometry. n = four independent experiments; *p < 0.05 versus vehicle.
(D and E) Graphs of monocyte levels (D) and BM progenitor cells (E) in WT mice in response to vehicle or S100A8/S100A9 complex (20 mg/kg/mouse i.v., twice
daily for 3 days). n = 5/group; *p < 0.05 versus vehicle.
(F–I) S100a9/BMT study including experimental overview (WTmice were transplanted with BM from either WT or S100a9/mice andmade diabetic with STZ)
(F), blood leukocyte levels after 4 weeks of diabetes (G), and percentages of HSPCs, CMPs, and GMPs in the BM (H), or the G2/M phase of the cell cycle (I). n =
5/group. *p < 0.05 versus all groups. All values are means ± SEM.
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WT CD45.2 or (2) WT CD45.1 and Rage/ CD45.2 mice were
transplanted intoWT recipients andmade diabetic with STZ (Fig-
ure 3H). In group B recipients (Rage/ CD45.2 BM), there was
an overall decrease in the number of blood monocytes and
neutrophils (both CD45.1 and CD45.2 cells) compared to group
A recipients. Notably, however, there was no change in the ratio
of CD45.1 to CD45.2 cells in group B versus group A (Figure 3I).
These findings were mirrored in the BM progenitor cells (Figures
3J and 3K). The decrease in the total number of monocytes, neu-
trophils, CMPs, and GMPs without a preference for CD45.1 over
CD45.2 cells indicated that RAGE stimulated proliferation of
CMPs and GMPs in a non-cell-autonomous fashion. This would
be consistent with a model (Figure 3L) in which S100A8/S100A9
induces an inflammatory cytokine response on diabetic CMPs
where RAGE is highly expressed (Figure 3C), resulting in the
secretion of cytokines that, in turn, induce proliferation and
expansion of GMPs. Consistent with this, pharmacological inhi-
bition of NF-kB, which is central to RAGE signaling (Yao and
Brownlee, 2010), attenuated GMP proliferation in response to
S100A8/S100A9 (Figure 3M).
RAGE Signals via NF-kB to Stimulate Cytokine
Production
Exploring the potential mediators of GMP proliferation, we found
that S100A8/S100A9 dramatically elevated M-CSF, GM-CSF,
and G-CSF expression in BM cells via NF-kB (Figure 3N).
Further, antibody neutralization of M-CSF or GM-CSF reduced
S100A8/S100A9-induced GMP proliferation, while combined
neutralization abolished the proliferative effects of S100A8/
S100A9 (Figure 3O). To determine the source of the CSFs, we
isolated and cultured HSPCs, CMPs, and GMPs (from WT BM)
in HG ± S100A8/S100A9. M-CSF was mainly produced from
CMPs (Figures S5H and S5I). BM macrophages appeared to
be the main source of GM-CSF as determined by flow cytometry
(Figure S5J).
We next tested whether RAGE was required for M-CSF and
GM-CSF induction by S100A8/S100A9. BM deletion of either
S100A8/S100A9 or RAGE prevented hyperglycemia-induced
expression of these CSFs (Figures S5K and S5L). Together these
data are consistent with a model in which neutrophil-derived
S100A8/S100A9 interacts with RAGE on BM cells including
CMPs to induce M-CSF and GM-CSF, leading to GMP prolifera-
tion and increased production of monocytes and neutrophils
(Figure 3L).
Neutrophils Drive Myelopoiesis in Diabetes
To directly test whether neutrophil-derived S100A8/S100A9
causes hyperglycemia-induced myelopoiesis, we depleted
mice of circulating neutrophils using the neutrophil-specific
Ly6-G antibody (clone 1A8); this antibody does not interact
with circulating monocytes) (Daley et al., 2008) (Figure 4A).
Neutrophil deletion normalized monocyte levels in diabetic
mice (Figure 4B). Neutrophil-depleted diabetic mice also had
lower levels of S100A8/S100A9 in the plasma (Figure 4C) and
decreased numbers and proliferation of CMPs and GMPs
(Figures 4D and 4E). Diabetes-induced RAGE expression on
CMPs was unaltered by neutrophil depletion (Figure 4F). These
findings confirm that neutrophil-derived ligands (likely S100A8/CS100A9) are required to induce myelopoiesis and imply that
non-neutrophil-derived RAGE ligands are insufficient to drive
myelopoiesis.
Glucose Reduction Improves Atherosclerotic Lesion
Regression
To test the hypothesis that glucose-induced monocytosis is
responsible for defective lesion regression, we performed an
atherosclerosis regression study (Figure 5A; experimental
design). Regression in Ldlr/ mice with established, but un-
complicated, lesions was initiated by switching from a high-
cholesterol diet (0.15%) to a chow diet (Reg). Some mice were
made diabetic (Reg + STZ), and a subgroup was treated with
the SGLT2i (Reg + STZ + SGLT2i). After 6 weeks on chow diet,
all mice had similarly reduced plasma cholesterol levels; impor-
tantly, there was no difference in cholesterol levels between
the Reg + STZ and Reg + STZ + SGLT2i mice (Figure 5B). As
expected, Reg + STZ mice had monocytosis (Figure 5C), which
was accompanied by increased plasma levels of S100A8/
S100A9, enhanced expression of RAGE on CMPs, and expan-
sion and proliferation of CMPs and GMPs (Figures S6A–S6D).
Reducing blood glucose reversed these effects, ultimately
reducing the number of circulating Ly6-Chi monocytes.
Reg mice showed a marked reduction in lesion area; lipid (oil
red O) and macrophage content (CD68+ cells) were decreased
compared to baseline. Diabetes severely impaired the regres-
sion process. However, lowering plasma glucose significantly
improved lesion regression as shown by decreased lesion
area, lipid accumulation, and macrophage content (Figures 5D,
5E, and S6E).
mRNA analysis of lesional CD68+ cells revealed that the mac-
rophages in diabetic mice had increased production of inflam-
matory molecules (Figure S7A). This could be due to a number
of factors, including recruitment of inflammatory Ly6-Chi mono-
cytes. Consistent with increased Ly6-Chi monocyte recruitment,
we observed changes in a number of parameters of the cell
adhesion cascade, including an increase in the number (Fig-
ure 5C), activation (CD11b; Figure 5H), adhesion (Figure 5G),
and migration (Figure 5I) of Ly6-Chi monocytes from diabetic
(Reg + STZ) mice. There was a nonsignificant trend for increased
expression of ICAM-1 and VCAM-1 on the endothelial cells
covering the lesion (data not shown). Increased lesional Ly6-C
staining (Figure 5J) and Ccr2mRNA was consistent with greater
recruitment of Ly6-Chi (CCR2+) monocytes (Swirski et al., 2007;
Tacke et al., 2007) (Figure S7B). We also observed an increase
in the expression of a number of chemokines in lesional macro-
phages (Figure S7B), consistent with enhanced monocyte
recruitment. These key processes in the cell adhesion cascade,
along with the Ly6-C staining and expression of chemotactic
genes in the lesion, were all decreased by lowering blood
glucose levels.
Defective Lesion Regression in Diabetes Reflects
Persistent Monocyte Recruitment
The results from our regression study (Figure 5) pointed toward
changes in monocyte recruitment as the mechanism for defec-
tive lesion regression in diabetes. Defects in lesion regres-
sion can result from changes in monocyte entry (Potteaux
et al., 2011), macrophage egress (Trogan et al., 2006), or both.ell Metabolism 17, 695–708, May 7, 2013 ª2013 Elsevier Inc. 699
Figure 3. RAGE on Myeloid Progenitor Cells Mediates S100A8/S100A9-Stimulated Leukocytosis in Diabetic Mice
(A) GMP proliferation in response to S100A8/S100A9 (2 mg/ml) as measured by EdU incorporation. n = four independent experiments. *p < 0.05 versus vehicle in
each genotype.
(B) Blood leukocyte levels in WT and Rage/ mice with and without STZ diabetes. n = 5 or 6/group. *p < 0.05 versus all groups.
(C) Surface expression of RAGE on CMPs (histogram and quantification) in WT and STZ-diabetic mice treated with SGLT2i. n = 6; *p < 0.05 versus all groups,
*p < 0.05 versus WT + STZ.
(D) Experimental overview: WT mice were transplanted with BM from WT or Rage/ mice and made diabetic with STZ.
(E–G) After 4 weeks of diabetes, blood leukocytes (E), BM HSPC, CMP, GMP numbers (F), and proliferation (G) were measured by flow cytometry. n = 5/group;
*p < 0.05 versus all groups.
(legend continued on next page)
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Figure 4. Neutrophils Drive Hyperglycemia-
Mediated Leukocytosis in Diabetes
(A–F) Neutrophils in WT and STZ-diabetic mice
were depleted by injecting anti-Ly6G antibody
(clone 1A8, 1 mg/mouse by i.p. injection) every
3 days for 3 weeks. Neutrophil (A) and monocyte
(B) levels in WT and STZ mice treated with
anti-Ly6-G or an isotype control, plasma levels of
S100A8/S100A9 (C), CMP and GMP cell popula-
tions in the BM (D), CMP and GMP cell prolifera-
tion assessed by DAPI staining and represented
as percentage of cells in theG2/Mphase of the cell
cycle (E), and surface expression of RAGE on
CMPs (F). For all experiments, n = 5/group. *p <
0.05 indicated diabetes effect, ^p < 0.05 indicated
anti-Ly6G effect. All values are means ± SEM.
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in diabetic mice, we performed fate mapping studies using two
different models: aortic transplantation (Trogan et al., 2006)
and diet-induced regression. To assess monocyte entry, athero-
sclerotic segments of the aorta were transplanted into Akita
mice, which were injected with fluorescent beads to label their
monocytes 48 hr before sacrifice (Figure 6A; outline). Compared
to untreatedmice, there was a significant reduction in the uptake
of beads in the lesions of SGTL2i-treated Akita mice (Figure 6B),
indicating reduced monocyte entry and recruitment. To deter-
mine the effect of glucose reduction on egress of monocytes
and macrophages from lesions, we transplanted arteries from
animals in which arterialCD68+ cells were derived from EdU-
labeled Ly6-Chi monocytes. A group of donor mice were killed
to assess the amount of EdU+ labeling in aortic arch lesions,
and this served as a baseline measurement to calculate egress.
There was a similar reduction of EdU+ cells in lesions of the
transplanted aortas in both groups of Akita mice (Figure 6C),
suggesting that blood glucose did not affect the emigration of
macrophages from lesions.
To further explore the effect of glucose reduction on Ly6-Chi
monocyte entry and egress, we used a combination approach
involving both EdU and bead fate mapping of monocytes in
diet-induced regression model (Figure 6D; outline). We em-
ployed clodronate liposomes to deplete circulating monocytes(H–K) Competitive BMT study including experimental overview (equally mixed portions of CD45.1 and CD45
planted intoWTCD45.2 recipients andmade diabetic with STZ (H), numbers of CD45.1 and CD45.2 monocyte
percentages of CD45.1 and CD45.2 CMPs and GMPs (J), and percentages of CD45.1 and CD45.2 CMPs and
BM (K). Data are means ± SEM; n = 5 or 6/group. Numbers in parentheses indicate ratio of CD45.1:CD45.2
(L) Scheme summarizing the cell-extrinsic proliferative pathway induced by S100A8/S100A9-RAGE signalin
(M) GMP proliferation in response to S100A8/S100A9 ± the NF-kB inhibitor (SN50, 20 mM).
(N) mRNA of M-CSF, GM-CSF, and G-CSF as quantified by quantitative RT-PCR (qRT-PCR). n = 4 indep
^p < 0.05 versus HG.
(O) GMP proliferation in response to S100A8/S100A9 ± neutralizing antibodies to M-CSF and/or GM-CSF
independent experiments. *p < 0.05 versus ISO vehicle, ^p < 0.05 versus respective ISO control. All values
Cell Metabolism 17, 695and specifically labeled Ly6-Chi cells
with fluorescent beads (Tacke et al.,
2007). This was done at week 4 of the
regression period, with a group of mice
sacrificed 4 days after liposome injection
(48 hr after injecting the fluorescentbeads). This allowed us to examine recruitment of Ly6-Chi mono-
cytes to the lesion. This data also provided a baseline value of the
number of Ly6-Chi monocytes in order for us to determine mono-
cyte retention and egress rates in the respective regressing
lesions. At 48 hr before the end of the regression period
(T = 48 hr), we also labeled circulating Ly6-Chi monocytes
with EdU as a confirmatory measure of monocyte entry into
the atheroma. The number of Ly6-Chi cells that entered lesions
from the Reg + STZ groupwas significantly greater, asmeasured
by the number of EdU+ cells or beads per lesion (Figures 6F and
6G). While there was increased retention of macrophages as
determined by the absolute number of beads in the lesion after
the regression period (Figure 6G), the percentage of egress
was similar in both groups (Figure 6H), consistent with our find-
ings in the aortic transplant model (Figure 6C). Moreover, our
lesional macrophage gene expression data revealed that Ccr7,
a key receptor for macrophage egress (Fo¨rster et al., 1999;
Trogan et al., 2006), was decreased in diabetic mice, but not
reversed by glucose lowering (Figure S7B), which also supports
the conclusion that egress levels are similar in both groups of
mice. We acknowledge that EdU is incorporated into the DNA
of dividing cells, and our data could also be affected in part by
macrophage proliferation or apoptosis in the lesions; however,
the data obtained with EdU were consistent with that obtained
with fluorescent beads. Importantly, taken together, these data.2 BM from the respective genotypes were trans-
s and neutrophils from the respective donor BM (I),
GMPs in the cell cycle from each respective donor
. *p < 0.05 versus w/w.
g.
endent experiments. *p < 0.05 versus all groups,
or isotype controls (ISO) (all 30 mg/ml). n = four
are means ± SEM.
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Figure 5. Defective Lesion Regression in Diabetic Mice Is Improved by Normalizing Plasma Glucose
(A) Experimental overview: Ldlr/–micewere fed a HCD (0.15%) for 16 weeks to develop atherosclerotic lesions. At this time point, a group of mice was sacrificed
to determine baseline (preregression) lesion characteristics. The remaining mice were divided into three groups (Reg, Reg + STZ, and Reg + STZ + SGLT2i) and
placed on chow diet for 6 weeks (n = 10 or 11/group).
(B) Blood glucose and total cholesterol levels at baseline and after 6 weeks of regression. *p < 0.05 versus all groups.
(C) Blood leukocyte levels at baseline and after 6weeks of regression as assessed by flow cytometry. n = 9–11/group. *p < 0.05 versus all groups, ^p < 0.05 versus
Reg + STZ.
(D) Quantification of mean lesion areas.
(E) Representative oil red O-stained lesions and quantification of oil red O stain as percent of lesion area.
(legend continued on next page)
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monocytes into lesions is responsible for greater macrophage
content in hyperglycemia and impaired lesion regression.
S100A8/S100A9 Is Associated with Leukocytosis and
the Prevalence of CAD in T1D Patients
To determine if total WBC count, leukocyte subsets, and
S100A8/S100A9 levels correlate with CAD in T1DM, we
analyzed data from the 18th year follow up of the Pittsburgh
Epidemiology of Diabetes Complications (EDC) Study. T1DM
patients with CAD had increased numbers of WBCs, mono-
cytes, and neutrophils and serum levels of S100A8/S100A9
(Figure 7A). In univariate analysis, total WBCs, neutrophil counts,
and monocyte counts were all significantly associated with CAD
in the 290 participants with odds ratios (ORs) of 1.44, 1.64, and
1.56, respectively. However, after adjusting for other established
risk factors, only neutrophil count remained independently
associated with CAD (OR 1.65, p = 0.03). In a subgroup of 49
subjects, we measured serum S100A8/S100A9 levels and found
a borderline association with CAD (OR 1.45, p = 0.06), which
was a stronger correlate than total WBCs (1.20, p = 0.31).
Further analysis revealed a positive correlation between serum
S100A8/S100A9 and both neutrophils and WBCs (Figures 7B
and 7C).
To examine if S100A8/S100A9 promotes myelopoiesis using
human cells, we stimulated cultured hematopoietic progenitor
cells obtained from human cord blood (CD34+ cells) with
S100A8/S100A9. CD34+ cells cultured in HG and varying con-
centrations of S100A8/S100A9 showed a dose-dependent
increase in proliferation (Figure 7D) and in production of CD14+
monocytes (Figure 7E).
DISCUSSION
We have shown that hyperglycemia causes increased produc-
tion of inflammatory cells in the bone marrow, monocytosis,
and neutrophilia and impairs atherosclerotic lesion regression.
In response to hyperglycemia, neutrophils produce S100A8/
S100A9, which interacts with glucose-inducible RAGE on
CMPs, resulting in the release of inflammatory Ly6-Chi cells.
The enhanced and persistent entry of these cells into lesions
impairs regression. Normalizing blood glucose facilitated resolu-
tion by dampening S100A8/S100A9-initiated monocytosis and
causing an overall decrease in inflammatory status (summarized
in Figure 7F). These observations demonstrate a previously
unknown crosstalk between diabetic neutrophils and myeloid
progenitor cells, leading to increased production of monocytes
and neutrophils, and provide a mechanistic link between
diabetes and CAD.
Diabetes is generally considered to be an inflammatory state
(Wellen and Hotamisligil, 2005), but the underlying mechanisms(F) Representative CD68+-stained lesions and quantification as CD68+ area/lesio
(G) Ly6-Chi monocyte adhesion assay. FACS-isolated Ly6-Chi blood monocytes
allowed to adhere to cultured human aortic endothelial cells (HAECs) under stati
(H) Activation status of monocytes as measured by MFI of CD11b.
(I) Migration index for Ly6-Chi monocytes (FACS sorted) as determined by their ra
all groups; ^p < 0.05 versus Reg + STZ; n = 4/group.
(J) Representative images and quantification of lesions stained with Ly6-C antib
Arrows indicate Ly6-C+ cells (Ly6-Chi monocytes). Data are means ± SEM; n = 1
Care not well understood. Surprisingly, we discovered prominent
monocytosis and neutrophilia in two commonly used mouse
models of T1DM. Mice with defective cholesterol efflux path-
ways due to deficiency of Apoe or Abca1/Abcg1 also have
leukocytosis; these studies have provided evidence that
increased entry of circulating monocytes into lesions promotes
atherogenesis (Murphy et al., 2011; Potteaux et al., 2011;
Robbins et al., 2012; Swirski et al., 2007; Tacke et al., 2007;
Yvan-Charvet et al., 2010). In part, these changes reflected a
cell-autonomous proliferation and expansion of hematopoietic
stem and progenitor cells in the bonemarrow linked to increased
levels of growth factor receptors (Murphy et al., 2011; Yvan-
Charvet et al., 2010). However, our investigations in the diabetic
mouse models uncovered a distinctive set of mechanisms
underlying the increased production of inflammatory cells. First,
monocytosis and neutrophilia could be completely dissociated
from effects of hypercholesterolemia, since they were observed
in normolipidemic chow-fed diabetic mice. Rather, making use
of a glycosuric agent, we were able to demonstrate a direct
effect of hyperglycemia on myelopoiesis. Moreover, increased
production of monocytes and neutrophils was associated not
with expansion of the stem cell pool, but rather with increased
proliferation and numbers of CMPs and GMPs, and shown to
be mediated by cell-extrinsic factors. Increased production of
S100A8/S100A9 by neutrophils stimulated RAGE on CMPs
and led to secretion of CSFs that induced proliferation of
GMPs and increased production of monocytes and neutrophils.
Although S100A8/S100A9 and RAGE have been previously
implicated in diabetic inflammation and atherogenesis, these
studies have uncovered a signaling axis in which diabetes led
to increased expression of RAGE in CMPs, mediating an
augmented BMproliferative response to the elevated production
of S100A8/S100A9 from neutrophils.
Previous studies have reported increased levels of S100A8/
S100A9 in the plasma and lesions of diabetic mice (Soro-
Paavonen et al., 2008). However, the specific role of these
proteins in atherosclerosis has been controversial. Deletion of
S100A9 reduced atherosclerosis in one study performed on
the Apoe/ background (Croce et al., 2009), while transplant
of S100a9/ BM into Ldlr/ mice did not affect lesion size
(Averill et al., 2011). These discrepancies could be due to
different genetic backgrounds and disease states, but impor-
tantly, neither of these studies was conducted in the setting of
diabetes.
RAGE has been previously implicated in atherosclerosis but
not as a receptor mediating increased production of inflamma-
tory cells. Deletion of RAGE globally (Soro-Paavonen et al.,
2008) or in hematopoietic cells (Morris-Rosenfeld et al., 2011)
reduces atherosclerosis, likely by dampening the production of
inflammatory mediators. Previous studies implicating RAGE in
diabetic atherosclerosis have mainly suggested that RAGEn. *p < 0.05 versus Reg and Reg + STZ + SGLT2i, ^p < 0.05 versus Reg + STZ.
were labeled with cell tracker green, and equal numbers of monocytes were
c conditions. *p < 0.05 versus all groups; ^p < 0.05 versus Reg + STZ.
te and ability to migrate toward CCL2 (in a transwell chamber). *p < 0.05 versus
ody (FITC; green) and Hoechst dye (blue; nuclei) using confocal microscopy.
0/group. *p < 0.05 versus all groups; ^p < 0.05 versus REG + STZ.
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Figure 6. Impaired Lesion Regression in Diabetic Mice Is Due to Increased Monocyte Recruitment
(A) Ldlr/mice were fed a HCD for 16 weeks to develop atherosclerotic lesions. Aortic transplantation model overview: all donor Ldlr/mice were injected with
EdU (1mg i.v.) to label newly formedmonocytes. At 48 hr postinjection, aortas were dissected from thesemice and either processed for baselinemeasurement of
EdU+ cells or transplanted into chow-fed Akita mice ± SGLT2i. At 48 hr prior to termination, mice were injected with green fluorescent microspheres to determine
monocyte entry.
(B) Monocyte entry determined by fluorescent beads.
(C) Monocyte egress: representative images showing EdU stain (red) in the aortic arch sections of donor mice (baseline) and grafts from Akita and Akita + SGLT2i.
(D) Quantification of monocyte egress as represented by the number of EdU+ cells per section. *p < 0.05 versus baseline, n = 5/group.
(E) Diet-induced regression model overview: Ldlr/mice fed with a HCD for 16 week were divided into three groups (Reg, Reg + STZ, and Reg + STZ + SGLT2i)
and placed on chow diet. At the end of 4 weeks, all mice were injected (i.v.) with clodronate liposomes (CLO, 250 ml) to deplete the circulating monocytes. They
were injected with green fluorescent microspheres 48 hr later; 4 days later, a portion of mice from each group was sacrificed to determine the baseline
(legend continued on next page)
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Figure 7. S100A8/S100A9 Correlates with
Leukocytes in T1DM Patients with CAD
and Stimulates Myelopoiesis in Human
CD34+ Progenitor Cells
(A) Leukocyte and S100A8/S100A9 levels in T1DM
patients with and without CAD.
(B and C) Regression analysis: S100A8/S100A9
versus WBCs (B) and S100A8/S100A9 versus
neutrophils (C). n = 49.
(D) Proliferation of CD34+ progenitor cells to
increasing doses of S100A8/S100A9 was mea-
sured by EdU incorporation. n = four independent
experiments; data are means ± SEM; *p < 0.05
versus control.
(E) Production of CD14+ monocytes from CD34+
progenitor cells to increasing doses of S100A8/
S100A9. n = four independent experiments; data
are means ± SEM; *p < 0.05 versus control.
(F) Model describing the mechanisms of mono-
cytosis and its effects on lesion regression in T1D.
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(Bucciarelli et al., 2002; Harja et al., 2008; Park et al., 1998;
Soro-Paavonen et al., 2008). However, a seminal study by
Reaven et al. (1997) revealed that accumulation of AGEs does
not influence atherosclerosis. Our studies indicate that ligands
other than AGEs, notably S100A8/S100A9, are important for
RAGE activation and its inflammatory effects.
Our study using murine atherosclerosis regression models
shows that persistent monocytosis and increased monocyte
entry into lesions likely contributes to the previously documented
impaired regression in diabetes (Parathath et al., 2011). These
findings provide conceptual support for the work of Potteauxmeasurement of beads in the atheroma and to assess Ly6-Chi monocyte entry. A second group of mice was
quantification of labeled macrophages remaining in plaques. At 48 hr prior to sacrificing the final group of m
monocyte entry.
(F) Ly6-Chi monocyte entry as determined by EdU+ cells in the lesion.
(G) Ly6-Chi monocyte entry and monocyte and macrophage retention in the lesion as assessed by number
(H) Percentage of macrophage egress compared to baseline. *p < 0.05 versus all groups, ^p < 0.05 final versus
Cell Metabolism 17, 695et al. (2011), demonstrating that persis-
tent monocyte entry into lesions may
contribute to impaired regression, and
show that excessive bone marrow pro-
duction of inflammatory cells contributes
to this process. While increased macro-
phage production of chemokines was
likely an important factor in both studies,
our study reveals a coordinated process
in which increased production and activa-
tion of monocytes is coupled with
enhanced calling of cells into the inflam-
matory milieu of the plaque. An important
implication is that normalizing monocyte
production and decreasing monocyte
influx into the plaque may be an avenue
by which lesion regression in the setting
of diabetes could be facilitated. Glucose
reductionmay also have beneficial effects
on macrophages and other cells in theatheroma, including vascular smooth muscle and regulatory
T cells (Bornfeldt and Tabas, 2011).
A limitation of our study is that our untreated diabetic mice
were not under any form of glucose control, unlike diabetic
patients in which glucose is usually controlled. Therefore, it is
possible that the hyperglycemia-driven leukocytosis observed
in our mouse models is dampened in humans. However, inter-
mittent spikes of hyperglycemia appear to be sufficient to
develop leukocytosis (Ford, 2002; Persson et al., 1998; Schmidt
et al., 1999; Vuckovic et al., 2007; Woo et al., 2011), likely by
S100A8/S100A9-mediated mechanisms. These hyperglyce-
mia-induced changes in WBCs could affect vascular disease.assessed 14 days later (6 weeks of regression) for
ice, they were injected with EdU to assess Ly6-Chi
of beads/section.
baseline; n = 6/group. All values aremeans ± SEM.
–708, May 7, 2013 ª2013 Elsevier Inc. 705
Cell Metabolism
Hyperglycemia, Myelopoiesis, and AtherosclerosisSuggesting human relevance of our mechanistic mouse
studies, we found a significant correlation among leukocytes,
serum S100A8/S100A9, and the incidence of CAD in a subset
of T1DM patients from the Pittsburgh EDC study. While these
data only describe correlations and not a direct role for
S100A8/S100A9, our in vitro studies using human CD34+ cells
also suggest that our findings in the mouse may be translatable
to these patients. These findings are also consistent with other
studies in which plasma S100A8/S100A9 concentration (Healy
et al., 2006) or circulating leukocyte numbers (Orchard et al.,
2003) independently predict future CAD.
Although our studies largely focused on hyperglycemia in
insulin-deficient mouse models of diabetes, patients with either
T1DM or T2DM have increased leukocyte counts (Ford, 2002;
Schmidt et al., 1999; Tong et al., 2004; van Oostrom et al.,
2004) and are at a greater risk of developing CAD. Our study in
mouse models strongly suggests that hyperglycemia per se pro-
motes monocyte production in patients with diabetes, and this
may be a factor contributing to a higher risk of CAD. Thus, our
findings highlight the potential importance of glucose control
and lipid-lowering therapy as strategies to promote regression
of atherosclerosis in diabetics and also suggest a number
of therapeutic targets, including disruption of the S100A8/
S100A9-RAGE signaling axis.
EXPERIMENTAL PROCEDURES
Mice and Treatments
In this study, we used 8- to 12-week-old male mice (wild-type, Ins2Akita/J,
S100a9/, Ldlr/, Rage/, and Myd88/ in C57BL/6 backgrounds).
Diabetes was induced by streptozotocin (STZ; 50 mg/kg intraperitoneally
[i.p.] for 5 days). Sodium glucose transporter 2 inhibitors (SGLT2i) from ISIS
Pharmaceuticals and Bristol-Myers Squibb were administered in drinking
water at a dose of 5 mg and 25 mg/kg (body weight), respectively. Mice in
the STZ- and Akita diabetic groups were treated for 4 weeks with the SGLT2i,
while Ldlr/ mice in the atherosclerosis regression study were treated for
6 weeks. Unless specifically indicated, all diabetic mice were treated with
SGLT2i from ISIS Pharmaceuticals at a dose of 5 mg/kg/day in drinking water.
For S100A8/S100A9 and HMGB1 in vivo studies, WT mice were injected
with vehicle or human recombinant proteins (10 mg/kg intravenously [i.v.]) twice
a day for 3 days, after which their blood and BM cells were analyzed by flow
cytometry.
Flow Cytometry
Blood Leukocytes
Leukocyte subsets were identified from whole blood as previously described
(Murphy et al., 2011). EDTA anticoagulated blood was subjected to red blood
cell (RBC) lysis. WBCs were resuspended in flow buffer (Hank’s balanced salt
solution + 0.1% BSA w/v, 5 mM EDTA) and stained with a cocktail of
antibodies. Monocytes were identified as CD45hiCD115hi and subsets as
Ly6-Chi and Ly6-Clo; neutrophils were identified as CD45hiCD115loLy6-C/Ghi
(Gr-1). CD11b mean fluorescent intensity (geometric mean) was measured
as marker of monocyte activation (Murphy et al., 2008).
Hematopoietic Stem Cells
Hematopoietic stem and progenitor cells were analyzed by flow cytometry as
previously described (Murphy et al., 2011). BM was harvested from femurs
and tibias, and the RBCs were lysed. The cell suspension incubation with
a cocktail of antibodies against lineage-committed cells (B220, CD19,
CD11b, CD3e, TER-119, CD2, CD8, CD4, Ly6-C/Ly6-G, all fluorescein iso-
thiocyanate [FITC]) was performed. This was accompanied by markers
to identify the stem and progenitor cells that were identified as HSPCs (line-
age, Sac1+, and ckit+), CMPs (lineage, Sca1, ckit+, CD34int, and FcgRIIint/
FcgRIIIint), and GMPs (lineage, Sca1, ckit+, CD34int, and FcgRIIhi/FcgRIIIhi).
RAGE expression was measured using a primary antibody to RAGE706 Cell Metabolism 17, 695–708, May 7, 2013 ª2013 Elsevier Inc.followed by a fluorescently conjugated secondary antibody. Cell-cycle anal-
ysis was performed using DAPI. Flow cytometry was performed using an LSR
II (for analysis) or FACSAria (for sorting); both machines ran FACSDiva
software. All flow cytometry data were analyzed using FlowJo software
(Tree Star).
Detailed methods are available as Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.cmet.2013.04.001.
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